Latest Pharma & Healthcare Insights

New ultra-sensitive test has been developed for cancer and HIV

Company Report

 March 20, 2016 Stanford researchers said that another ultra-sensitive test designed and intended to recognize diseases including cancer and HIV might demonstrate 10,000 times more successful than current diagnostic tools. At the point when an illness - whether it is a tumor or an infection like HIV - starts developing in the body, the immune system reacts by creating antibodies. Taking these antibodies or related biomarkers out of the blood is one method by which researchers infer the vicinity of a disease. 

It includes developing an atom to which the biomarker will bind and which is embellished with a distinguishing "flag." Analysts can disengage that flag, and the biomarker bound to it, to give an intermediary estimation of the ailment through a progression of specific chemical reactions, known as an immunoassay.

The new method, created in the lab of Carolyn Bertozzi, professor at Stanford University in US, expands this standard strategy with effective DNA screening technology. The scientific experts have supplanted the standard flag with a short strand of DNA, which can then be teased out of the sample utilizing DNA isolation methods that are significantly more sensitive than those workable for conventional antibody detections. 

Peter Robinson, a graduate understudy in Bertozzi's gathering said that "This is profoundly identified with an essential science tool we were creating to recognize protein modifications, however we understood that the core principles were really clear and that the methodology may be better off as a diagnostic tool". The researchers tested their system with its specific DNA flag, against four commercially accessible, USFDA endorsed tests for thyroid cancer biomarker. It beat the affectability of every one of them, by no less than 800 times, and up to 10,000 times, specialists said. 

Physicians could hypothetically come down with diseases far prior in their progression by distinguishing the disease biomarkers at lower concentrations. Robinson said that "the thyroid malignancy test has generally been a genuinely difficult immunoassay, since it delivers a considerable measure of false positives and false negatives, so it was doubtful if our test would have any advantage". Cheng-ting Tsai, a graduate in Bertozzi's group said “as opposed to numerous new indicative techniques, this test is performed on previous machines that most clinical labs are now acquainted with". The study was published in ACS Central Science.

According to Pharmaion, pharma and healthcare consultants recent report, United States Cancer Biomarker Market Opportunities, 2011 - 2021”, a clinical trial in progress in a joint effort with the Alameda County Public Health Laboratory will assess the procedure as a screening tool for HIV. Early recognition and treatment of the infection and virus can guarantee that its impacts on the patient are minimized and diminish the chance of its transmission to others. 

 

Relevant Reports

India Pharmacy Market Opportunities, 2011 - 2021

Pharmaceutical | 22 Aug, 2016News

India is the second most populated country globally, with a total population of 1.3 billion as of 2015. More than 50% of the country’s population is in the age group of <25 years. India accounted for ~20% share in the global

Relevant News